Skip to main content
BioCentury
As published for the week of Monday, January 19, 2015


  • Cover Story: Strategy: Partitioning HCV

    Handicapping the HCV price war; Medicaid wild card

    By Erin McCallister, Senior Editor

    Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total lives covered. But much of the population is still up for grabs, and the real victor in share of lives could be determined by how the U.S. Department of Veterans Affairs and Medicaid plans respond.

    Since FDA approved AbbVie's Viekira Pak paritaprevir/ritonavir/ombitasvir/dasabuvir regimen to treat HCV genotype 1, the pharma and Gilead have been competing for exclusive formulary status by trading rebates for access. Gilead markets Harvoni ledipasvir/sofosbuvir and Sovaldi sofosbuvir.

    Full Article

Money Raised in 2015

Last week, the biotech industry raised $6,836 million, bringing to $10.7 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $21.5 billion in debt, $11.1 billion in follow-ons, $3.9 billion in PIPEs and other equity, $9 billion in IPOs, and $9 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial